IMPROVING THE LIVES

OF PATIENTS WITH CANCER AND
INFLAMMATORY DISEASES.

Clinical Pipeline

Clinical Pipeline

One deep-rooted belief we hold here at Enzychem Lifesciences is that any form of treatment should be accessible to patients all over the world. As we pursue to develop a global new drug, our team carries the important duty of ensuring EC-18’s efficacy backed up by comprehensive studies. Enzychem has commenced clinical trials in 2016, and since then, we have been conducting ongoing research in the drug’s effects on patients with one of various conditions.

Read More
Clinical Program

Clinical Program

The global drug development program at Enzychem entails an extensive sequence of clinical studies on the safety and efficacy of EC-18 in various indications.

Read More

Latest News

October 02, 2020 Enzychem Lifesciences Selected to Present at 2020 Radiation Research Society Annual Meeting Read More
September 22, 2020 EC-18 Could Be South Korea’s Next Global Blockbuster Drug by Ki Young Sohn, Chairman of Enzychem Lifesciences Read More
August 14, 2020 Enzychem Lifesciences Announces FDA Acceptance of Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 Pneumonia Read More
July 14, 2020 Enzychem Lifesciences Files IND Application to FDA for Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 Pneumonia Read More